Literature DB >> 22120925

The impact of factor Xa inhibition on axial dependent arterial thrombus formation triggered by a tissue factor rich surface.

Nicholas Pugh1, Gavin E Jarvis, Annelize Koch, Kjell S Sakariassen, Bill Davis, Richard W Farndale.   

Abstract

This study was designed to assess the effect of Factor Xa antagonists on thrombus formation at various axial positions on a tissue factor rich surface under arterial blood flow conditions. Non-anticoagulated, flowing human blood, drawn directly from an antecubital vein, was perfused over a tissue factor coated cover slip in a parallel-plate perfusion chamber. Thrombus surface coverage, thrombus mean height and fibrin surface coverage were measured at six different axial positions by confocal microscopy. Both thrombus surface coverage and mean height decreased along the cover slip axis whereas the fibrin surface coverage increased. Pre-chamber treatment of blood with the direct Factor Xa inhibitors Razaxaban and 813893 resulted in significantly reduced thrombus and fibrin formation at all axial positions investigated (P < 0.05). Thrombus and fibrin deposition in a laminar flow chamber changed with axial position with surface coverage measurements being more reproducible than thrombus mean height. Data were more reproducible towards the centre of the flow chamber than at the extremities. Razaxaban and 813893 inhibited thrombus and fibrin formation at the highest concentrations tested. No difference in drug effect was apparent at different axial positions. In conclusion, axial position influences the degree of thrombus and fibrin deposition with measurements being less reproducible at the extremities of the flow chamber. This technique may prove useful for analysing anti-thrombotic drug effects before progression to clinical trials.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22120925     DOI: 10.1007/s11239-011-0658-6

Source DB:  PubMed          Journal:  J Thromb Thrombolysis        ISSN: 0929-5305            Impact factor:   2.300


  27 in total

1.  Factor Xa--a promising target for drug development.

Authors:  B Kaiser
Journal:  Cell Mol Life Sci       Date:  2002-02       Impact factor: 9.261

2.  Antithrombotic potential of GW813893: a novel, orally active, active-site directed factor Xa inhibitor.

Authors:  Melanie A Abboud; Saul J Needle; Cynthia L Burns-Kurtis; Richard E Valocik; Paul F Koster; Augustin J Amour; Chuen Chan; David Brown; Laiq Chaudry; Ping Zhou; Angela Patikis; Champa Patel; Anthony J Pateman; Rob J Young; Nigel S Watson; John R Toomey
Journal:  J Cardiovasc Pharmacol       Date:  2008-07       Impact factor: 3.105

3.  Synergism between platelet collagen receptors defined using receptor-specific collagen-mimetic peptide substrata in flowing blood.

Authors:  Nicholas Pugh; Anna M C Simpson; Peter A Smethurst; Philip G de Groot; Nicolas Raynal; Richard W Farndale
Journal:  Blood       Date:  2010-03-29       Impact factor: 22.113

4.  Application of the Cavalieri principle in volume estimation using laser confocal microscopy.

Authors:  Y S Prakash; K G Smithson; G C Sieck
Journal:  Neuroimage       Date:  1994-11       Impact factor: 6.556

Review 5.  Blood flow and antithrombotic drug effects.

Authors:  S R Hanson; K S Sakariassen
Journal:  Am Heart J       Date:  1998-05       Impact factor: 4.749

6.  Early potent antithrombotic effect with combined aspirin and a loading dose of clopidogrel on experimental arterial thrombogenesis in humans.

Authors:  Y Cadroy; J P Bossavy; C Thalamas; L Sagnard; K Sakariassen; B Boneu
Journal:  Circulation       Date:  2000-06-20       Impact factor: 29.690

7.  Design and synthesis of orally active pyrrolidin-2-one-based factor Xa inhibitors.

Authors:  Nigel S Watson; David Brown; Matthew Campbell; Chuen Chan; Laiq Chaudry; Máire A Convery; Rebecca Fenwick; J Nicole Hamblin; Claudine Haslam; Henry A Kelly; N Paul King; Cynthia L Kurtis; Andrew R Leach; Gary R Manchee; Andrew M Mason; Charlotte Mitchell; Champa Patel; Vipulkumar K Patel; Stefan Senger; Gita P Shah; Helen E Weston; Caroline Whitworth; Robert J Young
Journal:  Bioorg Med Chem Lett       Date:  2006-05-11       Impact factor: 2.823

8.  A double-blind randomized comparison of combined aspirin and ticlopidine therapy versus aspirin or ticlopidine alone on experimental arterial thrombogenesis in humans.

Authors:  J P Bossavy; C Thalamas; L Sagnard; A Barret; K Sakariassen; B Boneu; Y Cadroy
Journal:  Blood       Date:  1998-09-01       Impact factor: 22.113

9.  Antithrombotic effects of factor Xa inhibition with DU-176b: Phase-I study of an oral, direct factor Xa inhibitor using an ex-vivo flow chamber.

Authors:  Mohammad Urooj Zafar; David A Vorchheimer; Juan Gaztanaga; Mauricio Velez; Daniel Yadegar; Pedro R Moreno; Satoshi Kunitada; Juan Pagan; Valentin Fuster; Juan J Badimon
Journal:  Thromb Haemost       Date:  2007-10       Impact factor: 5.249

10.  Comparative real-time effects on platelet adhesion and aggregation under flowing conditions of in vivo aspirin, heparin, and monoclonal antibody fragment against glycoprotein IIb-IIIa.

Authors:  N A Turner; J L Moake; S G Kamat; A I Schafer; N S Kleiman; R Jordan; L V McIntire
Journal:  Circulation       Date:  1995-03-01       Impact factor: 29.690

View more
  1 in total

Review 1.  Whole Blood Based Multiparameter Assessment of Thrombus Formation in Standard Microfluidic Devices to Proxy In Vivo Haemostasis and Thrombosis.

Authors:  Isabella Provenzale; Sanne L N Brouns; Paola E J van der Meijden; Frauke Swieringa; Johan W M Heemskerk
Journal:  Micromachines (Basel)       Date:  2019-11-16       Impact factor: 2.891

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.